CN102743552B - 一种解烟清肺茶及其制备方法 - Google Patents
一种解烟清肺茶及其制备方法 Download PDFInfo
- Publication number
- CN102743552B CN102743552B CN201210282232.1A CN201210282232A CN102743552B CN 102743552 B CN102743552 B CN 102743552B CN 201210282232 A CN201210282232 A CN 201210282232A CN 102743552 B CN102743552 B CN 102743552B
- Authority
- CN
- China
- Prior art keywords
- parts
- camelliae sinensis
- folium camelliae
- adjuvant
- medicinal liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000019504 cigarettes Nutrition 0.000 title claims abstract description 26
- 210000004072 lung Anatomy 0.000 title claims abstract description 25
- 241001122767 Theaceae Species 0.000 title claims description 17
- 238000002360 preparation method Methods 0.000 title claims description 12
- 239000007788 liquid Substances 0.000 claims abstract description 18
- 239000002671 adjuvant Substances 0.000 claims abstract description 15
- 238000001816 cooling Methods 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 241000190633 Cordyceps Species 0.000 claims abstract description 7
- 241000628997 Flos Species 0.000 claims abstract description 7
- 210000000582 semen Anatomy 0.000 claims abstract description 7
- 238000009835 boiling Methods 0.000 claims abstract description 6
- 230000008030 elimination Effects 0.000 claims abstract description 6
- 238000003379 elimination reaction Methods 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims abstract description 6
- 230000000149 penetrating effect Effects 0.000 claims abstract description 6
- 238000007670 refining Methods 0.000 claims abstract description 6
- 239000004744 fabric Substances 0.000 claims description 5
- 230000000391 smoking effect Effects 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 20
- 206010068887 Tobacco poisoning Diseases 0.000 abstract description 16
- 230000002265 prevention Effects 0.000 abstract description 7
- 230000005586 smoking cessation Effects 0.000 abstract description 6
- 244000269722 Thea sinensis Species 0.000 abstract 1
- 230000000593 degrading effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 18
- 229960002715 nicotine Drugs 0.000 description 18
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 17
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 17
- 239000000126 substance Substances 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 6
- 206010006451 bronchitis Diseases 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 230000000607 poisoning effect Effects 0.000 description 6
- 208000023504 respiratory system disease Diseases 0.000 description 6
- 206010006458 Bronchitis chronic Diseases 0.000 description 5
- 208000007451 chronic bronchitis Diseases 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 4
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 4
- 229960004949 glycyrrhizic acid Drugs 0.000 description 4
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 4
- 235000019410 glycyrrhizin Nutrition 0.000 description 4
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 231100000572 poisoning Toxicity 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- BAHMQESJBKGPTE-UHFFFAOYSA-N 1,5,8-trimethyl-3a,4-dihydroazuleno[6,5-b]furan-2,6-dione Chemical compound C1C2OC(=O)C(C)=C2C=C2C(C)=CC(=O)C2=C1C BAHMQESJBKGPTE-UHFFFAOYSA-N 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000001473 noxious effect Effects 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 1
- HDXIQHTUNGFJIC-UHFFFAOYSA-N (25R)-spirost-5-en-3beta-ol 3-O-<O-alpha-L-rhamnopyranosyl-(1-->2)-beta-D-glucopyranoside> Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC1OC(CO)C(O)C(O)C1OC1OC(C)C(O)C(O)C1O HDXIQHTUNGFJIC-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- VNONINPVFQTJOC-RXEYMUOJSA-N Collettiside III Natural products O([C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](CO)O[C@@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@H](C)[C@@]6(O[C@H]5C4)OC[C@H](C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 VNONINPVFQTJOC-RXEYMUOJSA-N 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- VNONINPVFQTJOC-ZGXDEBHDSA-N dioscin Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O VNONINPVFQTJOC-ZGXDEBHDSA-N 0.000 description 1
- CJNUQCDDINHHHD-APRUHSSNSA-N dioscin Natural products C[C@@H]1CC[C@@]2(OC1)O[C@H]3C[C@H]4[C@@H]5CC=C6C[C@H](CC[C@@H]6[C@H]5CC[C@]4(C)[C@H]3[C@@H]2C)O[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O[C@@H]9O[C@@H](C)[C@H](O)[C@@H](O)[C@H]9O CJNUQCDDINHHHD-APRUHSSNSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- -1 flavone compounds Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000003546 flue gas Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000005264 laryngeal carcinoma Diseases 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- VNONINPVFQTJOC-UHFFFAOYSA-N polyphyllin III Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C(C1O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C1OC1OC(C)C(O)C(O)C1O VNONINPVFQTJOC-UHFFFAOYSA-N 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
一种解烟清肺茶,它包括辅料和茶叶,其中辅料中各组分按质量配比为:酸枣36—53份;金银花26—39份;甘草39—54份;蒲公英31—51份;山楂23—36份;决明子22—34份;虫草13—19份;山药24—38份;桑叶22—35份;按质量比8:1配比水和上述配方的辅料,煮沸后,滤去药渣,药液冷却后,将药液和精制的茶叶按质量比1:0.4混合,反复翻拌,使药液能均匀渗透茶叶中,湿度不沾手为宜,将其放置烤箱中烘烤,烘烤温度为120度,烘烤时间为30分钟,取出后自然冷却;本发明不仅降解烟毒以及烟毒引起的一系列病患具有很好的治疗预防功效,还对戒烟具有很好的效果,尤其适合烟龄较长的中老年人群。
Description
技术领域
本发明涉及一种解烟清肺茶及其制备方法。
背景技术
随着中国老龄化社会进程的加快,慢性支气管炎患病率随着年龄增长而递增,50岁以上的患病率高达15%或更多,疾病发展又可并发阻塞性肺气肿、肺源性心脏病,严重影响劳动和健康;现今公认吸烟为慢性支气管炎最主要的发病因素,吸烟能使支气管上皮纤毛变短,不规则,纤毛运动发生障碍,降低局部抵抗力,削弱肺泡吞噬细胞的吞噬、灭菌作用,又能引起支气管痉挛,增加气道阻力,具统计学结论其中吸烟者慢性支气管炎的患病率为不吸烟的2倍。具调查数据,中国烟民总数超过3亿,这成为慢性支气管炎的发病巨大的群体基数,如果不控制吸烟人数和解决吸烟对健康造成的不利后果,可以预期香烟所引起的健康问题势必会加重中国老龄化社会的负担,给国家和社会造成巨大的损失;公认的香烟燃烧后的尼古丁和焦油是对人体危害最大的物质,香烟在燃烧时产生近4000多种化学物质,烟气携带大量有毒物质沉降于人体肺部,导致肺部功能受损,同时这些有害物质进入人体,给人体带来更大的毒害,比如香烟中的尼古丁会通过肺部的肺泡、嘴唇表面等的毛细血管进入人体内,而进入人体内的尼古丁会增加血管中的胆固醇量,促使体内的血管收缩,加速动脉硬化和使人体内的维生素C含量下降,导致动脉内膜增厚、血糖高、胃酸分泌量显着减少等症状,导致高血糖和糖尿病等;再如吸烟者血液内溶有一定的焦油成分,并作用于血管管壁,加速血管硬化,对于脑血管和心血管这些脆弱部分更加敏感,近些年来,心脑血管疾病是影响人们健康的第一杀手,与香烟有着直接关系;具世界卫生组织(WHO)统计,发达国家男性中90—95%肺癌,40—60%的各类癌症,75%—80%的慢性阻塞性肺部疾病,20—25%的冠心病均归因于吸烟;因此能及时清除吸烟后沉积人体肺部的有毒物质,就会减少香烟的毒害,从而降低相关疾病的发病率。同时为了健康,很多人选择戒烟,但是戒烟的最大困难就是尼古丁引起的烟瘾,由于尼古丁进入人体血液中,只有通过人体自身的新陈代谢才能排出体外,由于人体代谢周期决定了尼古丁所带来的兴奋将长期引诱戒烟者想吸烟的冲动,因此加快人体新陈代谢,加快尼古丁排出人体的速度,就能有效提高戒烟的成功率。
发明内容
本发明的目的在于提供了一种解烟清肺茶及其制备方法,它具有解烟毒、清肺润喉和制备工艺简单的优点。
本发明是这样来实现的,一种解烟清肺茶,其特征在于它包括辅料和茶叶,其中辅料中各组分按质量配比为:酸枣36—53份;金银花26—39份;甘草39—54份;蒲公英31—51份;山楂23—36份;决明子22—34份;虫草13—19份;山药24—38份;桑叶22—35份;其制备方法为:按质量比8:1配比水和上述配方的辅料,加入到容器中,用火煮沸后,滤去药渣,待药液冷却后,再将药液和精制的茶叶按质量比1:0.4混合,然后将茶叶反复翻拌,使药液能均匀渗透茶叶中,湿度不沾手为宜,最后将茶叶均匀的倒置于筛网中,将其放置烤箱中烘烤,烘烤温度为120度,烘烤时间为30分钟,最后取出后自然冷却。
酸枣含硒,具有抗氧化作用;更重要的是,酸枣含大量的维生素C,在人体中的利用率可达到86.3%,酸枣中含有大量维生素E,可以促进血液循环和组织生长;
金银花具有抗炎解毒、疏风解表、疏利咽喉,抗病原微生物和加强免疫机能作用;
甘草富含甘草甜素、甘草酸以及甘草次酸,甘草甜素水解产物葡萄糖醛酸,对进入血液中的毒物结合吸附,具有很好的解毒抗炎效果,甘草还具有祛痰止咳、平喘的作用,临床被广泛用于治疗各种急慢性肝炎和支气管炎等,甘草酸具有降血脂与抗动脉粥样硬化作用,阻止动脉粥样硬化的形成;
蒲公英植物体中含有蒲公英醇、蒲公英素、胆碱及维生素等,《医林纂要》中记载:蒲公英具有解毒散结的功效;
山楂富含黄酮类物质、维生素C、胡萝卜素、山楂酸等物质,能防治心血管疾病,具有扩张血管、强心、增加冠脉血流量、改善心脏活力、兴奋中枢神经系统、降低血压和胆固醇、软化血管及利尿和镇静作用;防治动脉硬化,防衰老、抗癌的作用,山楂酸还有强心作用,对老年性心脏病也有益处;
决明子富含有多种维生素和丰富的氨基酸,对降血压、降血脂、减少胆固醇等效果显著,对于防治冠心病、高血压都有不错的疗效;
冬虫夏草具有补肺肾、止咳嗽、益虚损、养精气之功能,并对肺部病菌具有杀伤力;
山药富含多种维生素、氨基酸和矿物质等,可以防治人体脂质代谢异常,以及动脉硬化,对维护胰岛素正常功能也有一定作用,有增强人体免疫力,益心安神,止咳定喘等保健作用;山药还富含薯蓣皂苷(C45H72O16),它有止咳、祛痰、脱敏、消炎作用,可用于气管炎的治疗;中医药理也记载:山药生津益肺的作用,治疗肺虚喘咳具有较好的效果;
桑叶富含大量的黄酮类化合物、多种生物碱、桑叶多糖等,具有排毒、降血压、血脂、抗炎等作用;
茶叶中丰富的维生素和茶多酚能够代替尼古丁带来的兴奋,茶叶中多酚类物质单宁和单宁酸可与香烟中尼古丁化合形成无毒复合物,茶叶还具有利尿,加快人体新陈代谢的作用,加快滞留人体内的烟毒的排出。
本发明的技术效果是:本发明不仅对戒烟具有很好的效果,还对烟毒以及烟毒引起的一系列病患具有很好的治疗预防功效,它结合传统茶文化与饮茶习惯,经过长期实践总结而成的,制备工艺简单,解烟清肺效果好,对长期吸烟引起的气管和心血疾病具有很好的治疗预防效果,兼具治疗和保健的功能,尤其适合烟龄较长的中老年人群。
具体实施方式
下面结合具体实施例对本发明做详细阐述,
实施例一、将辅料中各组分按质量配比为:酸枣41g;金银花30g份;甘草45g;蒲公英40g;山楂24g;决明子24g;虫草15g;山药35g;桑叶30g份;其制备方法为:按质量比8:1配比水和上述配方的辅料,加入到容器中,用火煮沸后,滤去药渣,待药液冷却后,再将药液和精制的茶叶按质量比1:0.4混合,然后将茶叶反复翻拌,使药液能均匀渗透茶叶中,湿度不沾手为宜,最后将茶叶均匀的倒置于筛网中,将其放置烤箱中烘烤,烘烤温度为120度,烘烤时间为30分钟,最后取出后自然冷却。
实施例二、将辅料中各组分按质量配比为:酸枣36g;金银花33g;甘草54g;蒲公英50g;山楂22g;决明子30g;虫草18g;山药37g;桑叶30g;其制备方法为:按质量比8:1配比水和上述配方的辅料,加入到容器中,用火煮沸后,滤去药渣,待药液冷却后,再将药液和精制的茶叶按质量比1:0.4混合,然后将茶叶反复翻拌,使药液能均匀渗透茶叶中,湿度不沾手为宜,最后将茶叶均匀的倒置于筛网中,将其放置烤箱中烘烤,烘烤温度为120度,烘烤时间为30分钟,最后取出后自然冷却。
实施例三、将辅料中各组分按质量配比为:酸枣40g;金银花36g;甘草50g;蒲公英50g;山楂35g;决明子22g;虫草17g;山药34g;桑叶31g;其制备方法为:按质量比8:1配比水和上述配方的辅料,加入到容器中,用火煮沸后,滤去药渣,待药液冷却后,再将药液和精制的茶叶按质量比1:0.4混合,然后将茶叶反复翻拌,使药液能均匀渗透茶叶中,湿度不沾手为宜,最后将茶叶均匀的倒置于筛网中,将其放置烤箱中烘烤,烘烤温度为120度,烘烤时间为30分钟,最后取出后自然冷却。
本发明经过长期实践,证明其具有良好的解烟清肺、治疗预防烟毒所引起的病患等效果;一方面,它对血液中烟毒的降解效率高,还降低了焦油等有害物质在肺部的吸附沉积,另一方面,长期服用本发明的解烟清肺茶,会补助人体维生素,改善心血管系统以及呼吸系统,治疗和预防烟毒对人体的毒害。
本发明的解烟清肺茶用法:一般一日两次,一次4—6克为宜,用温开水冲泡即可。
对本发明降解血液中烟毒效果,由于焦油很难被人体吸收而进入血液,本次烟毒检测主要为血液中的尼古丁含量,进行了实验对比,对象共选择37人,烟龄为5年的男性,年龄在25—30周岁,过程为:(1)实验过程中,特要求每人一天抽5只烟(硬盒中华牌香烟),每次抽烟时间间隔为120分钟,每天早晚抽血化验尼古丁含量两次,连续三天,求血液中平均尼古丁含量,检测结果记录表1;(2)然后也要求每人一天抽5只烟,每次抽烟时间间隔为120分钟,早晚各饮用实施例一制备的解烟清肺茶5g,温开水冲泡饮用,每天早晚抽血化验尼古丁含量两次,连续三天,求血液中平均尼古丁含量,检测结果记录表2;
上述实验结果不具有统计学意义,但是通过上述对比分析,完全可以得出如下结论:本发明制备的解烟清肺茶对降解血液中烟毒的主要成分—尼古丁效果较好,明显降低了烟毒在血液中的含量,因此,解烟清肺茶对降低烟毒对人体的危害具良好的作用。
另外在本次实验过程中,跟踪观察了实验过程(2)中实验对象的吸烟欲望的表现,大量临床实验证明,尼古丁浓度维持时间一般为吸烟后的20分钟左右,血液中高浓度尼古丁对人体中枢神经有一定兴奋作用,由于人体自身排毒作用,吸烟后40分钟左右,血液中尼古丁浓度会明显下降,吸烟者会表现出明显的再次吸烟欲望,而本次实验中,吸烟者普遍超过100分钟后才表现出明显的再次吸烟欲望,吸烟者自己也普遍表示,相对以前,吸烟后想再次吸烟的时间间隔明显延长,对香烟的依赖程度明显减轻,这对戒烟具有重要意义。
本发明对降低吸烟者心血系统以及呼吸系统疾病也有良好的预防与治疗效果;发明人对解烟清肺茶相关效果进行了长期的对比与分析;
实践中,选取年龄45—55周岁的烟民自愿者,剔除有相关心血系统以及呼吸系统疾病病史的自愿者,共有128人参加了本次实验,实验对象每天饮用实施例二制备的解烟清肺茶,一日两次,一次4—6g,连续服用1年,统计相关病患情况记载在表3,连续服用2年,统计相关病患情况记载在表4;另调查本地区45—65周岁的烟民相关心血系统以及呼吸系统疾病发病率,记载在表5;调查中对同时患有心血系统和呼吸系统疾病的自愿者以较重病情归入其中一种病患种类,其中调查的心血系统包括冠心病、心脏病、高血压、血栓、血管硬化等,呼吸系统疾病包括支气管炎,肺癌、喉癌、咽炎、肺气肿等。
在实践中,由于烟民烟龄以及身体素质等因数没有考虑在内,在对比调查表5中,人数也存在参差不齐等,缺乏一定的科学严谨性,但通过对比表3、4与表5可以看出,本发明的解烟清肺茶对治疗和预防中老年烟民常见病效果好,能够明显降低中老年烟民中心血系统和呼吸系统疾病发病率,它一方面补充人体由于吸烟而大量丢失的维生素以及其他人体必需微量元素,另一方面控制烟毒在人体内的浓度,减少烟毒对人体心血系统的毒害,并且滋肺化痰、止咳定喘、提高肺部自我修复能力和肺部生理机能。
Claims (1)
1.一种解烟清肺茶,它包括辅料和茶叶,其中辅料中各组分按质量配比为:酸枣36—53份;金银花26—39份;甘草39—54份;蒲公英31—51份;山楂23—36份;决明子22—34份;虫草13—19份;山药24—38份;桑叶22—35份;其特征在于其制备方法为:按质量比8:1配比水和上述配方的辅料,加入到容器中,用火煮沸后,滤去药渣,待药液冷却后,再将药液和精制的茶叶按质量比1:0.4混合,然后将茶叶反复翻拌,使药液能均匀渗透茶叶中,湿度不沾手为宜,最后将茶叶均匀的倒置于筛网中,将其放置烤箱中烘烤,烘烤温度为120度,烘烤时间为30分钟,最后取出后自然冷却。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210282232.1A CN102743552B (zh) | 2012-08-10 | 2012-08-10 | 一种解烟清肺茶及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210282232.1A CN102743552B (zh) | 2012-08-10 | 2012-08-10 | 一种解烟清肺茶及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102743552A CN102743552A (zh) | 2012-10-24 |
CN102743552B true CN102743552B (zh) | 2015-11-18 |
Family
ID=47024281
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210282232.1A Active CN102743552B (zh) | 2012-08-10 | 2012-08-10 | 一种解烟清肺茶及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102743552B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103783213B (zh) * | 2012-11-05 | 2016-06-01 | 任恢捷 | 一种虫草养生保健茶 |
CN109892686A (zh) * | 2019-03-20 | 2019-06-18 | 福建绿色黄金生物科技有限公司 | 一种茶与冬虫夏草组合物、制备方法及其应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101623091A (zh) * | 2008-07-08 | 2010-01-13 | 刘泳宏 | 一种天然五色中药茶及制作方法 |
-
2012
- 2012-08-10 CN CN201210282232.1A patent/CN102743552B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101623091A (zh) * | 2008-07-08 | 2010-01-13 | 刘泳宏 | 一种天然五色中药茶及制作方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102743552A (zh) | 2012-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104957298A (zh) | 养生茉莉花茶 | |
CN100393226C (zh) | 三参解烟排毒保健茶 | |
CN105148017B (zh) | 一种具有润肺止咳功能的饮料 | |
CN102613705A (zh) | 一种具有保健功能的香烟过滤嘴 | |
CN103564647A (zh) | 一种烟用中药香料的制备方法 | |
CN103417820B (zh) | 用于排解烟毒、康复机能、减烟控烟的中药制品及其制备方法 | |
CN101427844A (zh) | 无花果保健香烟 | |
CN104000195B (zh) | 清肺排毒口服液及其生产方法 | |
CN103719491A (zh) | 一种黄精健脾润肺保健茶及其制备方法 | |
CN101455442B (zh) | 一种葡萄浸膏及其制备方法和在卷烟加香中的应用 | |
CN106692673A (zh) | 汉方清肺茶组合物及其制备方法 | |
CN102743552B (zh) | 一种解烟清肺茶及其制备方法 | |
CN101496635A (zh) | 金银菊复合吸品 | |
CN101803799A (zh) | 含有绞股蓝总甙的香烟及其制备方法 | |
CN103417875B (zh) | 一种治疗慢性支气管炎的中药制剂及其制备方法 | |
CN100500015C (zh) | 解烟排毒五花仙茶 | |
CN111642786B (zh) | 一种具有防疫和保健功效的中草药茶烟及其应用 | |
CN100551282C (zh) | 一种减少杂气、降低刺激、提升烟香的天然烟用添加剂及其制备方法 | |
CN107334867A (zh) | 一种动物用抗感颗粒及其制备方法 | |
CN104352589B (zh) | 一种以人参为主要原料的中药戒烟液及其制备方法 | |
CN103272196B (zh) | 解毒的药物组合物和药物制剂及其制备方法 | |
CN105617268A (zh) | 一种治疗鳞屑角化型脚气的药物 | |
CN105362704A (zh) | 一种清热利咽饮料及其制备方法 | |
CN104083495A (zh) | 一种用于治疗老年性失眠的中药 | |
CN107362318A (zh) | 一种安神解郁的离子化中药组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170801 Address after: 330001, No. 13, No. 3, 99 Hubin East Road, Qingshan Lake District, Jiangxi, Nanchang, 7 Patentee after: Nanchang Qiangbo agricultural science and Technology Co. Ltd. Address before: 330000 No. 1486, Beijing East Road, Jiangxi, Nanchang Patentee before: Li Jiaxian |
|
TR01 | Transfer of patent right |